The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.

Inclusion Criteria:

• Diagnosed with bacterial conjunctivitis in 1 or both eyes;
• Able to understand and sign an informed consent form. If subject is <18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative;
• Agrees to comply with the visit schedule and other requirements of the study;
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Day 1;
• Presence of concomitant viral infection;
• Infants with ophthalmia neonatorum of gonococcal, Chlamydia, herpetic or chemical origin;
• Infants whose birth mothers had any sexually transmitted disease within 1 month prior to delivery;
• Infants undergoing treatment for retinopathy of prematurity;
• Contact lens wear during the course of the study;
• Only 1 sighted eye or vision in either eye not correctable to 0.6 logMAR units (20/80) or better;
• Use of medications, as specified in the protocol;
• Any systemic or ocular disease or disorder, complicating factors or structural abnormality that could negatively affect the conduct or outcome of the study;
• Known or suspected allergy or hypersensitivity to fluoroquinolones;
• Pregnant, lactating, or of childbearing potential and not using adequate birth control to prevent pregnancy;
• Other protocol-specified exclusion criteria may apply.

This population analysis includes all subjects who received study drug (Safety Analysis Set).

Baseline through study completion, an average of 4 days

An AE was defined as any untoward change (expected or unexpected) in a patient's ophthalmic and/or medical health that occurred after initiation of study treatment. AEs were obtained as solicited comments from the study patient/guardian and as observations by the study investigator.